Functional testing plays central role in care of glaucoma patients

Article

Visual field testing can be frustrating for patients, but it should remain a core component of patient care because it provides essential information about glaucoma progression.

Key Points

Salt Lake City-Visual field testing (VFT) can be frustrating for patients, but it should remain a core component of patient care because it provides essential information about glaucoma progression, said Michael Chaglasian, OD, at Optometry's Meeting.

"As a bottom line," he continued, "identifying progression in glaucoma is difficult, and no single modality of evaluation should be used in isolation. Monitoring requires a combination of visual fields, structural analysis, and clinical and photographic assessment. Clinicians should become comfortable with all of these tools and know the strengths and limitations of the systems they are using in order to optimize individual patient care."

Currently, standard automated perimetry-white-on-white-remains the gold standard for VFT in glaucoma. Dr. Chaglasian recommended using threshold algorithms, noting he most frequently uses the 24-2 SITA-standard program (Humphrey Field Analyzer [HFA], Carl Zeiss Meditec). Programs with a similar test pattern and number of stimulus locations are available on instruments from other manufacturers.

In evaluating serial visual fields, clinicians must recognize that in eyes with early glaucomatous functional loss, fluctuation in the location of defects is not uncommon. Data on the repeatability of visual function testing from the large, randomized, controlled OHTS showed that 86% of abnormal and reliable fields were not confirmed on retesting.

Other data from OHTS showed that a visual field abnormality confirmed by three consecutive, reliable results offered greater specificity. Yet, some eyes with three abnormal tests still had a normal test on subsequent follow-up.

"This reminds us of the need to carefully evaluate any field abnormality and to be cautious about making a diagnosis just based on a single visual field for a patient," Dr. Chaglasian told Optometry Times.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.